Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Beyond Air is a clinical-stage medical device company developing nitric oxide (NO) delivery systems for respiratory and other diseases. Its lead product, LungFit, delivers high-concentration NO for treatment of bronchiolitis, pneumonia, and lung infections in hospitalized patients. The company is pre-revenue, burning cash to fund clinical trials and regulatory submissions, with stock performance driven by FDA milestone progress and financing events.
Beyond Air's business model centers on commercializing proprietary nitric oxide generation technology that eliminates need for compressed gas cylinders. Revenue will derive from device placements in hospitals (capital equipment or rental model) plus recurring consumables/service contracts. Competitive advantage lies in portable, on-demand NO generation versus traditional cylinder-based systems, potentially offering hospitals lower logistics costs and improved workflow. Pricing power depends on demonstrating clinical superiority and cost-effectiveness versus standard-of-care antibiotics and existing NO delivery systems. Currently pre-commercial with negative gross margins reflecting R&D expenses capitalized as COGS.
FDA regulatory milestones for LungFit (510(k) clearance, De Novo classification decisions, or PMA submissions)
Clinical trial data readouts showing efficacy in bronchiolitis, pneumonia, or nontuberculous mycobacteria (NTM) lung infections
Partnership or licensing agreements with larger medical device companies or international distributors
Equity financing announcements and dilution concerns given cash burn rate and current ratio of 5.12x
Medicare/Medicaid reimbursement decisions for NO therapy in target indications
FDA regulatory rejection or delayed approval pathway for LungFit, extending cash burn and requiring additional clinical trials with uncertain outcomes
Reimbursement risk if payers decline coverage for NO therapy in target indications, limiting commercial viability despite FDA approval
Technological obsolescence if alternative respiratory therapies (novel antibiotics, inhaled therapeutics) demonstrate superior efficacy or cost-effectiveness
Established NO delivery systems from Mallinckrodt (INOmax) and Praxair dominate market with proven safety profiles and existing hospital relationships
Large medical device companies (Medtronic, GE Healthcare) could develop competing portable NO generation technology with superior distribution networks
Generic antibiotic competition and evolving standard-of-care protocols may limit addressable market for NO therapy
Severe cash burn with negative operating cash flow and 805.8% negative FCF yield creates imminent dilution risk or potential bankruptcy if financing unavailable
Debt/equity ratio of 3.06x suggests significant convertible debt that will dilute equity holders upon conversion, particularly if stock price remains depressed
Current ratio of 5.12x appears healthy but absolute cash balance likely insufficient for multi-year runway given -1202% operating margin; requires near-term capital raise
low - As a pre-revenue clinical-stage company, Beyond Air has minimal direct exposure to economic cycles. Hospital capital equipment budgets can tighten during recessions, potentially delaying post-approval adoption. However, respiratory infections requiring hospitalization are non-discretionary, providing stable end-market demand. Primary sensitivity is to biotech financing conditions rather than GDP growth.
Rising interest rates negatively impact Beyond Air through multiple channels: (1) Higher discount rates compress NPV of future cash flows, particularly punitive for pre-revenue companies with distant profitability; (2) Increased cost of capital makes equity financing more dilutive; (3) Risk-off sentiment in rate-hiking cycles reduces speculative biotech investor appetite. With debt/equity of 3.06x, the company likely has convertible debt where rising rates increase refinancing costs. Valuation multiples for unprofitable growth companies contract sharply in rising rate environments.
Moderate credit exposure. Beyond Air requires access to capital markets to fund operations given negative free cash flow. Tightening credit conditions or widening high-yield spreads reduce availability and increase cost of convertible debt financing, a common funding source for clinical-stage companies. Investment-grade credit conditions less relevant as company unlikely to access traditional bank lending. Venture debt availability also correlates with overall credit market health.
growth - Attracts speculative biotech investors seeking asymmetric returns from binary FDA approval events. Typical holders include specialized healthcare hedge funds, venture capital crossover funds, and retail traders pursuing high-risk/high-reward clinical-stage opportunities. Not suitable for value or income investors given negative profitability and no dividend. Momentum traders enter around catalyst events (trial data, FDA submissions) but exit quickly on disappointment.
high - Stock exhibits extreme volatility typical of clinical-stage biotech with binary regulatory outcomes. 85.1% one-year decline and 53.4% six-month decline reflect failed milestones or financing concerns. Expect 20-50% single-day moves on FDA announcements or clinical data releases. Illiquid float amplifies volatility. Beta likely exceeds 2.0x relative to broader market. Options market typically prices elevated implied volatility around known catalyst dates.
